Type 2 Diabetes [clinicaltrials_resource:9d0b9265fabb266bda4551314039c119]
Low Carbohydrate Diet Compared to Calorie and Fat Restricted Diet in Patients With Obesity and Type II Diabetes [clinicaltrials:NCT00108459]Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes [clinicaltrials:NCT00141492]Breaking Down Barriers to Diabetes Self-Care [clinicaltrials:NCT00142922]Gene Expression Profiling and Bioinformatic Analysis Identifying Genes and Biochemical Pathways in Type 2 Diabetes [clinicaltrials:NCT00143013]Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes [clinicaltrials:NCT00143520]Prospective Study of Patients With Hirsutism [clinicaltrials:NCT00145288]Body Composition, Glucose Metabolism, Insulin Resistance and Gene Expression in Muscle Cells in Healthy Overweight Women [clinicaltrials:NCT00145392]WelChol® With Metformin in Treating Patients With Type 2 Diabetes [clinicaltrials:NCT00147719]clinicaltrials:NCT00147745WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes [clinicaltrials:NCT00147758]The Effects of Two Education Strategies About Insulin on Patient Preferences and Perceptions About Insulin Therapy [clinicaltrials:NCT00149331]WelChol® and Insulin in Treating Patients With Type 2 Diabetes [clinicaltrials:NCT00151749]Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes [clinicaltrials:NCT00151762]Ezetimibe and Simvastatin in Dyslipidemia of Diabetes [clinicaltrials:NCT00157482]Renal and Systemic Effects of NCX4016 in Patients With Type 2 Diabetes and Early Nephropathy [clinicaltrials:NCT00157508]Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) [clinicaltrials:NCT00157586]Abdominal Adipose Tissue Distribution in Type 2 Diabetic Patients Treated During 6 Months With Pioglitazone or Insulin [clinicaltrials:NCT00159211]Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes [clinicaltrials:NCT00160160]Effects of a Mediterranean Style Diet on Vascular Health in Type 2 Diabetes [clinicaltrials:NCT00163683]Effect of Glargine Insulin on Glucose Control in Hospitalized Patients Who Receive Tube Feedings [clinicaltrials:NCT00177398]Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes [clinicaltrials:NCT00191178]Sleep Apnea in Look AHEAD (Action for Health in Diabetes) [clinicaltrials:NCT00194259]Impact of Self-Monitoring Blood Glucose Frequency on Glycemic Control in Patients With Type 2 Diabetes [clinicaltrials:NCT00202033]Change of Lifestyle by Persons in Risk of Type 2 Diabetes [clinicaltrials:NCT00202748]Higher Dose of Ramipril Versus Addition of Telmisartan-Ramipril in Hypertension and Diabetes [clinicaltrials:NCT00208221]Exercise Training in Type 2 Diabetes and Hypertension [clinicaltrials:NCT00212303]Actos Now for Prevention of Diabetes (ACT NOW) [clinicaltrials:NCT00220961]Alberta Diabetes and Physical Activity Trial [clinicaltrials:NCT00221234]Canadian Trial of Dietary Carbohydrates in Diabetes [clinicaltrials:NCT00223574]Feasibility Study of Digital Photography and Group Discussion for People With Diabetes [clinicaltrials:NCT00225888]The ADDITION Study. Intensive Treatment in People With Screen Detected Diabetes in Primary Care. [clinicaltrials:NCT00237549]A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1 [clinicaltrials:NCT00239187]clinicaltrials:NCT00239707A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics [clinicaltrials:NCT00240370]Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus [clinicaltrials:NCT00241085]Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy. [clinicaltrials:NCT00251680]GALLANT 7 Tesaglitazar Add-on to Sulphonylurea [clinicaltrials:NCT00251940]GALLANT 8 Tesaglitazar Add-on to Metformin [clinicaltrials:NCT00251953]clinicaltrials:NCT00252694GALLANT 2 Tesaglitazar vs. Placebo [clinicaltrials:NCT00252772]
condition [clinicaltrials_vocabulary:condition]
eligibility for clinicaltrials:NCT01667783 [clinicaltrials_resource:0d0b4187f161339187497f8ba78dc1ce]eligibility for clinicaltrials:NCT02046395 [clinicaltrials_resource:2f7d79148da83409b2089e78d4bb6279]eligibility for clinicaltrials:NCT01308008 [clinicaltrials_resource:38ef4f8b2517fbbf4ed94357d32c93e6]eligibility for clinicaltrials:NCT02037867 [clinicaltrials_resource:3e0f065604f09155eed6b3e1cd56185b]eligibility for clinicaltrials:NCT00162240 [clinicaltrials_resource:44b2a7daedb42612a0236bc976fd8fa3]eligibility for clinicaltrials:NCT00543621 [clinicaltrials_resource:509ef17c3234c42fe71f708ee910ad0e]eligibility for clinicaltrials:NCT00673231 [clinicaltrials_resource:6b04187adafb873e6ba7e0e0d049e3bb]eligibility for clinicaltrials:NCT01980524 [clinicaltrials_resource:6b388e1719b9b0e23b254eac587494fe]eligibility for clinicaltrials:NCT00819975 [clinicaltrials_resource:71da81cc41c7b7c90521a65343107d29]eligibility for clinicaltrials:NCT00660907 [clinicaltrials_resource:840026c1df873b3a8de789838f2a768a]eligibility for clinicaltrials:NCT00330473 [clinicaltrials_resource:8cf24d8ada942b351624f78d4d611d5d]eligibility for clinicaltrials:NCT00231725 [clinicaltrials_resource:938cbe6454b1fbf6c746bb98c76c5a2b]eligibility for clinicaltrials:NCT00486291 [clinicaltrials_resource:97b74414466d30cd5bcdf82d48a2ffb2]eligibility for clinicaltrials:NCT00424411 [clinicaltrials_resource:ac5cb4edd07cd6ebc2876c5f7a0e00bb]eligibility for clinicaltrials:NCT02207777 [clinicaltrials_resource:ae3b85623479dce6a2b716af7440b6d9]eligibility for clinicaltrials:NCT00797186 [clinicaltrials_resource:ae673d8817f36cb3bbeb75b4e394938e]eligibility for clinicaltrials:NCT02329366 [clinicaltrials_resource:ae87c399d4891f1ae15e1b638ca0de41]eligibility for clinicaltrials:NCT02305355 [clinicaltrials_resource:b0edf96afe0320b7ae9c467b6b3e3f52]eligibility for clinicaltrials:NCT01462877 [clinicaltrials_resource:b1ec8d74f1845bd112470c5682a04670]eligibility for clinicaltrials:NCT00235014 [clinicaltrials_resource:b7864ca358f18ed51edc5a5af446e2cf]eligibility for clinicaltrials:NCT01101204 [clinicaltrials_resource:bcce868ae95d97192daea1fd58579ca1]eligibility for clinicaltrials:NCT00523393 [clinicaltrials_resource:bcd66a7abae02d22f005eecdd848ac40]eligibility for clinicaltrials:NCT00350701 [clinicaltrials_resource:c626fce140de457acd97c3b6faa886a1]eligibility for clinicaltrials:NCT00106808 [clinicaltrials_resource:c677bcad8ff429cacdb414f9e7396d2f]eligibility for clinicaltrials:NCT01917669 [clinicaltrials_resource:d8d6ed13fa8e9585b8b59a6395fff37b]eligibility for clinicaltrials:NCT01671969 [clinicaltrials_resource:e30352d91ced53b7ab1ba8022bc6b738]eligibility for clinicaltrials:NCT00813930 [clinicaltrials_resource:ed3cb1e19fe3697acc084d4fe7195eb2]eligibility for clinicaltrials:NCT00457093 [clinicaltrials_resource:ee6b740d6173c7bdef86740e6c0b6d85]eligibility for clinicaltrials:NCT00680745 [clinicaltrials_resource:facc7a497e641009906ca993a23fadc4]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
eligibility for clinicaltrials:NCT00097877 [clinicaltrials_resource:078b3ee3cbd1d119d3e799033bc574de]eligibility for clinicaltrials:NCT01667783 [clinicaltrials_resource:0d0b4187f161339187497f8ba78dc1ce]eligibility for clinicaltrials:NCT02046395 [clinicaltrials_resource:2f7d79148da83409b2089e78d4bb6279]eligibility for clinicaltrials:NCT01308008 [clinicaltrials_resource:38ef4f8b2517fbbf4ed94357d32c93e6]eligibility for clinicaltrials:NCT02037867 [clinicaltrials_resource:3e0f065604f09155eed6b3e1cd56185b]eligibility for clinicaltrials:NCT00162240 [clinicaltrials_resource:44b2a7daedb42612a0236bc976fd8fa3]eligibility for clinicaltrials:NCT00543621 [clinicaltrials_resource:509ef17c3234c42fe71f708ee910ad0e]eligibility for clinicaltrials:NCT00673231 [clinicaltrials_resource:6b04187adafb873e6ba7e0e0d049e3bb]eligibility for clinicaltrials:NCT01980524 [clinicaltrials_resource:6b388e1719b9b0e23b254eac587494fe]eligibility for clinicaltrials:NCT00819975 [clinicaltrials_resource:71da81cc41c7b7c90521a65343107d29]eligibility for clinicaltrials:NCT00660907 [clinicaltrials_resource:840026c1df873b3a8de789838f2a768a]eligibility for clinicaltrials:NCT00330473 [clinicaltrials_resource:8cf24d8ada942b351624f78d4d611d5d]eligibility for clinicaltrials:NCT00231725 [clinicaltrials_resource:938cbe6454b1fbf6c746bb98c76c5a2b]eligibility for clinicaltrials:NCT00486291 [clinicaltrials_resource:97b74414466d30cd5bcdf82d48a2ffb2]eligibility for clinicaltrials:NCT00424411 [clinicaltrials_resource:ac5cb4edd07cd6ebc2876c5f7a0e00bb]eligibility for clinicaltrials:NCT02207777 [clinicaltrials_resource:ae3b85623479dce6a2b716af7440b6d9]eligibility for clinicaltrials:NCT00797186 [clinicaltrials_resource:ae673d8817f36cb3bbeb75b4e394938e]eligibility for clinicaltrials:NCT02329366 [clinicaltrials_resource:ae87c399d4891f1ae15e1b638ca0de41]eligibility for clinicaltrials:NCT02305355 [clinicaltrials_resource:b0edf96afe0320b7ae9c467b6b3e3f52]eligibility for clinicaltrials:NCT01462877 [clinicaltrials_resource:b1ec8d74f1845bd112470c5682a04670]eligibility for clinicaltrials:NCT00235014 [clinicaltrials_resource:b7864ca358f18ed51edc5a5af446e2cf]eligibility for clinicaltrials:NCT01101204 [clinicaltrials_resource:bcce868ae95d97192daea1fd58579ca1]eligibility for clinicaltrials:NCT00523393 [clinicaltrials_resource:bcd66a7abae02d22f005eecdd848ac40]eligibility for clinicaltrials:NCT00350701 [clinicaltrials_resource:c626fce140de457acd97c3b6faa886a1]eligibility for clinicaltrials:NCT00106808 [clinicaltrials_resource:c677bcad8ff429cacdb414f9e7396d2f]eligibility for clinicaltrials:NCT01917669 [clinicaltrials_resource:d8d6ed13fa8e9585b8b59a6395fff37b]eligibility for clinicaltrials:NCT01671969 [clinicaltrials_resource:e30352d91ced53b7ab1ba8022bc6b738]eligibility for clinicaltrials:NCT00813930 [clinicaltrials_resource:ed3cb1e19fe3697acc084d4fe7195eb2]eligibility for clinicaltrials:NCT00457093 [clinicaltrials_resource:ee6b740d6173c7bdef86740e6c0b6d85]eligibility for clinicaltrials:NCT00680745 [clinicaltrials_resource:facc7a497e641009906ca993a23fadc4]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
Type 2 Diabetes [clinicaltrials_resource:9d0b9265fabb266bda4551314039c119]
Bio2RDF identifier
9d0b9265fabb266bda4551314039c119
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:9d0b9265fabb266bda4551314039c119
identifier
clinicaltrials_resource:9d0b9265fabb266bda4551314039c119
title
Type 2 Diabetes
@en
type
label
Type 2 Diabetes [clinicaltrials_resource:9d0b9265fabb266bda4551314039c119]
@en